Human Technopole, Milan, Italy.
Group of Childhood Cancer and Blood Disorders, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Spain.
Mol Oncol. 2023 May;17(5):718-721. doi: 10.1002/1878-0261.13404. Epub 2023 Mar 8.
The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC-I). Cornel et al. showed that epigenetic modulation of neuroblastoma cells with a histone deacetylase inhibitor can boost the expression of major histocompatibility complex class I, among other immune receptors, priming their recognition by T- and natural killer cells. By leveraging the developmentally related aberrant epigenetic landscapes of neuroblastoma, these discoveries pave the way to overcome a major limitation in the field of neuroblastoma immunotherapy.
神经母细胞瘤的免疫疗法的发展仍然具有挑战性，这是由于神经母细胞瘤细胞的免疫原性低，主要表现为免疫识别的主要触发因素之一，即主要组织相容性复合体 I 类（MHC-I）的表达水平低。Cornel 等人表明，使用组蛋白去乙酰化酶抑制剂对神经母细胞瘤细胞进行表观遗传修饰，可以提高主要组织相容性复合体 I 类等免疫受体的表达，从而使其被 T 细胞和自然杀伤细胞识别。通过利用神经母细胞瘤发育相关的异常表观遗传景观，这些发现为克服神经母细胞瘤免疫治疗领域的一个主要限制铺平了道路。
